Mechanisms of resistance to PARP inhibitors-three and counting

Cancer Discovery

Volumn 3, Issue 1, 2013, Pages 20-23

  Fojo, Tito ^a   Bates, Susan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; AZD 2461; BRCA1 PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TARIQUIDAR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TRANSPORT; HOMOLOGOUS RECOMBINATION; NONHUMAN; PROTEIN PROCESSING; SINGLE STRANDED DNA BREAK; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84872868283     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0514     Document Type: Article

References (16)

1. Jaspers JE, Kersbergen A, Boon U, Sol W, Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013;3(1):68-81.
2. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007;104:12117-12122.
3. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105: 17079-17084.
4. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res 2009;69:6396-6404.
5. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine D A, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-1115.
6. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Ta rgeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012;15:50-61.
7. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012; 24: 150-154
8. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-244.
9. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-251.
10. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-1734.
11. Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010; 16: 4517-4526.
12. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 defi ciency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-695.
13. Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-defi cient cells by blocking resection of DNA breaks. Cell 2010;141:243-254.
14. Xie A, Hartlerode A, Stucki M, Odate S, Puget N, Kwok A, et al. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian doublestrand break repair. Mol Cell 2007;28:1045-1057.
15. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-5599.
16. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-509.